Morgan Stanley’s ABVC BioPharma ABVC Stock Holding History

Morgan Stanley’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,175	Closed	-$11K	–	8290
2025 Q4	$11K	Buy	+5,175	New	+$13.9K	﹤0.01%	6868
2022 Q2	–	Sell	-146	Closed	-$4K	–	7772
2022 Q1	$4K	Sell	146 -3	-2%	-$80	﹤0.01%	7618
2021 Q4	$5K	Buy	+149	New	+$4.67K	﹤0.01%	7627

Other funds holding ABVC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Morgan Stanley's ABVC Position: Q1 2026 in Review

Morgan Stanley sold out of ABVC BioPharma (ABVC) in Q1 2026, closing a stake of 5,175 shares — an estimated $11K sold.

Morgan Stanley first reported a position in ABVC in Q4 2021 and held it in 3 quarters. The position peaked at $11K in Q4 2025. 13 funds tracked by Wall St. Rank hold ABVC as of Q1 2026.

Morgan Stanley reported no remaining ABVC BioPharma position as of Q1 2026 after selling out during the quarter.
Morgan Stanley sold 5,175 ABVC BioPharma shares in Q1 2026, an estimated $11K.
Morgan Stanley first reported a position in ABVC BioPharma in Q4 2021 and held it in 3 quarters.
Morgan Stanley's ABVC BioPharma position peaked at $11K in Q4 2025.
13 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.